Jim Birchenough

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone

Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use

Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone

Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use

Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook

Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4

Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook

Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4

Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update

After Biogen's Alzheimer's Update, Wall Street Reacts

Jim Birchenough Recent News

Uniqure Notches Bullish Initiation On Gene Therapy Prospects

Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades

Bellicum Rallies After FDA Lifts Clinical Hold

Akcea Therapeutics Downgraded By Wells Fargo After Huge Run

Wall Street Reacts To Celgene's Reported Interest In Juno

Arena Pharma Upgraded Ahead Of Clinical Data Release

Infinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference Presentation

FDA Warning Letter Buckles Intercept Pharma Shares; Wells Fargo Downgrades

Analysts Weigh In On Gilead-Kite Pharma Deal

Clinical Hold For Regulus' RG101 Sparks A Downgrade At Wells Fargo

Legal Experts Weigh In On The Amgen/Regeneron Patent Case

Global Blood Therapeutics Shares Spiking On Analyst's Positive Outlook

Ziopharm Oncology Downgraded By BMO As 'Questions Persist'

BMO: Celgene Still A Buy On This 'Important Future Driver'

BMO Capital: Five Prime Therapeutics Still A Buy, Worth $31/Share Now

Regeneron Shares Fall Following BMO's Note Of Roche Preference

Ariad Shares Continue to Surge Amidst Buyout Rumors

UPDATE: BMO Capital Markets Upgrades Tesaro

Tesaro Shares Tumble After Disappointing Data Results

UPDATE: BMO Capital Markets Reiterates on Receptos Following Solid 3Q13 Operating Results

UPDATE: BMO Capital Markets Reiterates on Gilead Sciences Following Solid 3Q13 Results

UPDATE: BMO Capital Markets Downgrades Ariad Pharmaceuticals on AP26113 Disappointment, Tempered ICLUSIG Expectations

UPDATE: BMO Capital Markets Raises PT on Regulus Therapeutics Following 2Q13 Operating Results